Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs United Parcel Service Inc (UPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs United Parcel Service Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $300.09 (market cap $8.04B), while United Parcel Service Inc trades at $114.2 (market cap $96.62B). The key difference: United Parcel Service Inc is far larger — about 12× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and United Parcel Service Inc pays a 5.77% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | UPS | |
|---|---|---|
Market Cap | $8.04B | $96.62B |
Sector | Health | Industrials |
52-Week High | $339.75 | $120.00 |
52-Week Low | $241.71 | $82.58 |
Enterprise Value | $7.85B | $119.48B |
Volume | — | 2,288,643 |
Dividend Yield | — | 5.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
UPS stock trades at $112.89, up 0.37% today, with a bullish technical signal and consistent earnings beats. The company maintains solid profitability with a 5.94% net margin and 33.41% ROE, though revenue has declined from $100.3B in 2022 to $88.66B in 2025. Recent news highlights a $48 million investment in healthcare logistics and AI-driven efficiency improvements, while analyst sentiment is mixed with a consensus price target of $112.
The outlook for UPS is balanced; cost controls and strategic investments support margins, but revenue pressure and competitive threats from Amazon pose risks. The stock's valuation at a P/E of 18.27 is reasonable, yet growth headwinds and dividend sustainability concerns warrant caution. Upside depends on execution in logistics innovation and reversing top-line declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
